Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Premises for cholecystokinin and gastrin peptides in diabetes therapy

Research output: Contribution to journalReviewResearchpeer-review

DOI

  1. Gut Mucosal Gene Expression and Metabolic Changes After Roux-en-Y Gastric Bypass Surgery

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Limited diagnostic utility of Chromogranin A measurements in workup of neuroendocrine tumors

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Oral D/L-3-Hydroxybutyrate stimulates cholecystokinin and insulin secretion and slows gastric emptying in healthy males

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Bilio-enteric flow and plasma concentrations of bile acids after gastric bypass and sleeve gastrectomy

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Gastrin and cholecystokinin (CCK) are classical gastrointestinal peptide hormones. Their biogenesis, structures, and intestinal secretory patterns are well-known with the striking feature that their receptor-bound 'active sites' are highly homologous and that this structure is conserved for more than 500 million years during evolution. Consequently, gastrin and CCK are agonists for the same receptor (the CCK2 receptor). But in addition, tyrosyl O-sulphated CCK are also bound to the specific CCK1 receptor. The receptors are widely expressed in the body, including pancreatic islet-cell membranes. Moreover, CCK and gastrin peptides are at various developmental stages and diseases expressed in pancreatic islets; also in human islets. Accordingly, bioactive gastrin and CCK peptides stimulate islet-cell growth as well as insulin and glucagon secretion. In view of their insulinotropic effects, gastrin and CCK peptides have come into focus as drug targets, either alone or in combination with other insulinotropic gut hormones or growth factors. So far, modified CCK and gastrin peptides are being examined as potential drugs for therapy of type 1 as well as type 2 diabetes mellitus.

Original languageEnglish
Article number1179551419883608
JournalClinical medicine insights. Endocrinology and diabetes
Volume12
Number of pages6
ISSN1179-5514
DOIs
Publication statusPublished - 2019

ID: 58869941